SYNTHESIS AND CYTOTOXIC ACTIVITY OF 2,5-BIS(4-BORONIC ACID)BENZYLIDINE CYCLOPENTANONE ON HER2 OVEREXPRESSED-CANCER CELLS

Rohmad Yudi Utomo, Herwandhani Putri, Pudjono Pudjono, Ratna Asmah Susidarti, Riris Istighfari Jenie, Edy Meiyanto

Abstract


Development of chemotherapeutic agent and boron carrying pharmaceutical based on HER2 specific targeted is important due to its role in enhancing cancer progression. The purpose of this study is to synthesize curcumin analogue, namely Pentagamaboron-0 (PGB-0) or 2,5-bis(4-boronic acid)benzylidine cyclopentanone, and to explore the cytotoxic activity on HER2 overexpressed-cancer cells. MCF-7/HER2 was used as a model of HER2 overexpressed-cancer cells and NIH3T3 as normal cells. PGB-0 bound to ATP binding site of HER2 and EGFR based on molecular docking study. PGB-0 was synthesized resulting in 33% yield and was confirmed by IR, 1HNMR, 13CNMR and Mass spectroscopy. Based on MTT assay PGB-0 decreased cells viability on MCF-7/HER2 cells with IC50 value of 270 µM but performed no effect on NIH3T3 cells. Cell cycle analysis revealed that PGB-0 increased sub-G1 accumulation. PGB-0 decreased HER2 expression in a dose-dependent manner. We conclude that the new compound PGB-0 inhibits cell growth through cell death induction and decreased HER2 expression. Thus, PGB-0 is potential to be developed as a chemotherapeutic agent and boron carrying pharmaceutical targeted on the HER2 receptor.


Keywords


Synthesis of PGB-0; MCF7/HER-2; cytotoxic

Full Text:

PDF

References


Barth, R.F., 2005. Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects. Clin. Cancer Res. 11, 3987–4002.

Carpenter, R.L., Lo, H.-W., 2013. Regulation of Apoptosis by HER2 in Breast Cancer. J. Carcinog. Mutagen. 2013(Suppl 7), 003

D’Amato, V., Raimondo, L., Formisano, L., Giuliano, M., De Placido, S., Rosa, R., Bianco, R., 2015. Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat. Rev. 41, 877–883.

English, D.P., Roque, D.M., Santin, A.D., 2013. HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies. Mol. Diagn. Ther. 17, 85–99.

Gibbs, J.B., 2000. Anticancer drug targets: growth factors and growth factor signaling. J. Clin. Invest. 105, 9–13.

Hong, R.L., Spohn, W.H., Hung, M.C., 1999. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 5, 1884–1891.

Meiyanto, E., Hermawan, A., Anindyajati, 2011. Translational Research in Cancer Drug Development. Ind J Canc Chemoprev. 2, 198–210.

Meiyanto, E., Putri, D.D.P., Susidarti, R.A., Murwanti, R., Sardjiman, null, Fitriasari, A., Husnaa, U., Purnomo, H., Kawaichi, M., 2014. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac. J. Cancer Prev. 15, 179–184.

Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63.

Moy, B., Goss, P.E., 2006. Lapatinib: Current Status and Future Directions in Breast Cancer. The Oncologist 11, 1047–1057.

Nishiyabu, R., Kubo, Y., James, T.D., and Fossey, J.S., 2011, Boronic acid building blocks: tools for self assembly, Chem. Commun. 47, 1124-1150

Plavetić, N.D., Kulić, A., Vrbanec, D., 2012. Role of HER2 signaling pathway in breast cancer: biology, detection and therapeutical implications. Period. Biol. 114, 505–510.

Sardjiman, S.S., Reksohadiprodjo, M.S., Hakim, L., van der Goot, H., Timmerman, H., 1997. 1,5-Diphenyl-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. Eur. J. Med. Chem. 32, 625–630.

Vu, T., Claret, F.X., 2012. Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer. Front. Oncol. 2, 62

Yakes, F.M., Chinratanalab, W., Ritter, C.A., King, W., Seelig, S., Arteaga, C.L., 2002. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62, 4132–4141.




DOI: http://dx.doi.org/10.14499/indonesianjpharm28iss2pp74

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 INDONESIAN JOURNAL OF PHARMACY

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:

                                               

web
analytics View My Stats